Abstract: Novel etiology underlying certain types of seizures is presented, whereby changes in endocrine levels result in changes in osteoclast activity levels which in turn result in elevated extracellular Ca2+ levels which in turn result in systemic alterations in nerves, including increased membrane depolarization and enhanced neurotransmitter release, which in turn result in increased seizure risk in people with low seizure thresholds. Treatment methods are provided that modulate the bone microenvironment to provide an etiology based seizure treatment method based on the novel disclosures. The treatment methods include use of compounds such as calcitonin, SERMs such as raloxifene, testosterone, estrogen, calcimimetics such as cinacalcet, RANKL inhibitors such as denosumab, and bisphosphonates such as risedronate.

Abstract: The present invention provides a solid composition for oral administration comprising: (i) a drug compound; (ii) chitosan or a derivative thereof or a salt of chitosan or salt of a derivative of chitosan; and (iii) an organic acid. Preferably the drug compound is a polar molecule having a molecular weight of 1 KDa or less, a peptide, a protein or a polysaccharide. The compositions of the invention provide enhance absorption of the drug compound.

Abstract: The present invention relates to compositions including medium chain peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism. The compositions can include advantageously high levels of the medium chain peroxycarboxylic acid, can be readily made, and/or can exhibit reduced odor.

Abstract: The present invention is to provide a silver-based inorganic antimicrobial agent that has excellent heat resistance and chemical resistance, that gives little resin coloration, and that has excellent processability. It has been found that the object can be attained by a silver ion-containing zirconium phosphate represented by Formula (1) below by limiting the production conditions to wet synthesis, and the present invention has thus been accomplished. Aga MbZrc(PO4)3.nH2O??(1) In Formula (1), M is at least one type of ion selected from an alkali metal ion, a hydrogen ion, and an ammonium ion, a, b, and c are positive numbers and satisfy 1.5?c?2 and a+b+4c=9, and n is no greater than 2.

Abstract: Methods of growing and harvesting multiple species of phytoplankton are disclosed herein. The method generally includes four steps, namely: (1) collecting phytoplankton seawater containing multiple species of naturally-occurring phytoplankton directly from a source of seawater; (2) adding nutrients to the phytoplankton seawater to proliferate the multiple species of naturally-occurring phytoplankton to a predetermined density; (3) separating the multiple species of naturally-occurring phytoplankton from the phytoplankton seawater to form a phytoplankton concentrate; and (4) collecting the phytoplankton concentrate such that the collected phytoplankton of the phytoplankton concentrate remain in a substantially intact cellular state.

Abstract: The present invention relates to a composition for the relief of hangover symptoms and methods of treating hangover symptoms.

Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Abstract: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.

Abstract: A method of facilitating intracellular uptake or transcellular transport of cargo comprising: contacting target cells with a composition comprising an effective amount of cargo incorporated in a nanocarrier having a surface, wherein the nanocarrier surface comprises integrin-specific ligands having a surface density of approximately 5 to 50,000 integrin-specific ligands per ?m2, and maintaining contact between the composition and the target cells for a period of time sufficient to permit intracellular uptake or transcellular transport of the cargo.

Abstract: Formulations and blends are described comprising zinc, silver, bismuth and copper in non-toxic amounts that are useful as treatments of a wide variety of conditions and diseases promoted by bacteria or other microorganisms.

Abstract: Disclosed are systems, methods, compositions and kits for mineralizing tissue, particularly dental tissue. The methods, compositions and kits may be used to strengthen and prevent weakening of the tissue. For example, the methods, compositions and kits may be used for treating and filling cavities in teeth caused by tooth decay.

Abstract: The present invention is directed to a novel cement powder comprising an organic component consisting of one or more biocompatible and bioresorbable polymers and an inorganic component consisting of one or more calcium phosphate compounds. The invention also relates to the apatitic CPC resulting from the mixing of said cement powder with a liquid phase and setting.

Abstract: The present invention provides methods and compositions for providing long-term tube-fed nutrition. More specifically, the present invention provides methods and compositions for providing long-term tube-fed maintenance to a patient.

Abstract: The present invention provides the use of nanoparticles of a compound of general formula MnXy, where M is (i) a metal selected from the group consisting of Calcium (Ca), Aluminium (Al), Zinc (Zn), Nickel (Ni), Tungsten (W) or Copper (Cu); or (ii) a non-metal selected from the group consisting of Silicon (Si), Boron (B) or Carbon (C); in which n is equal to 1, 2, or 3, and X is (iii) a non-metal selected from the group consisting of Oxygen (O), Nitrogen (N), or Carbon (C); or (iv) an anion selected from the group consisting of phosphate (PO43?), hydrogen phosphate (HPO42?), dihydrogen phosphate (H2PO4?), carbonate (CO3), silicate (SiO42?), sulphate (SO42?), nitrate (NO3?), nitrite (NO2?); in which y is equal to 0, 1, 2, 3 or 4; for use in reducing and/or preventing virus transmission. Articles of protective clothing or filters are provided in which the fibres are coated with said nanoparticles for use in reducing and/or preventing virus transmission.

Abstract: The present invention relates to a method for providing cartilage proliferation generally comprising: supplying a dry potassium phosphate based mixture comprising: monobasic potassium phosphate, a metal oxide, and a tertiary calcium phosphate, wherein the weight percent ratio of monobasic potassium phosphate to metal oxide is between about 3:1 and 1:1; mixing the dry potassium phosphate based mixture with an aqueous solution forming an activated cartilage proliferating slurry (ACPS); applying an amount of the activated potassium phosphate based ACPS to a site of desired cartilage proliferation. In one or more preferred embodiments the dry mixture further comprises: a sugar (or sugar derivate/replacement) and/or mono-sodium phosphate.

Abstract: An object is to find a natural material having an activity of preventing the elevation of blood glucose level and to provide a means which is able to prevent or treat the diabetes and there is provided an agent for prevention or treatment of the elevated blood glucose level where a compound containing soluble silica and/or strontium is an active ingredient.

Abstract: A method for producing an agent against an infectious disease, particularly HIV, Ebola, or similar. In the method, a pressurized, especially medical oxygen is swirled into a solution containing at least one plant component particularly in the form of an extract.

Abstract: With a simple and high-yield production method, a zinc-containing sustained-release composition capable of stabilizing a physiologically active protein or peptide, typically G-CSF by precipitation and retaining drug efficacy for several days in a living body owing to its sustained releasability is provided. Concretely, a zinc-containing sustained-release composition produced by forming a precipitate by mixing a physiologically active protein or peptide, a water-soluble zinc salt, a water-soluble carbonate and/or a water soluble phosphate aqueous solution. The zinc-containing sustained-release composition may be administered as a zinc-containing sustained preparation by adding a pharmaceutically acceptable additive as is necessary.

Abstract: The invention refers to novel compositions with at least one prehormone, hormone from group consisting of mevalonate derivatives or from the group consisting of peptides and/or proteo-hormones and at least one mineral, one constituent by preference from the group consisting of iodine, selen and at least one Ginkgoloide against alkyl-acyl-GPC (AAGPC), its derivatives (alkyl-lipis) and/or products (e.g. acetylacyl-CoA). In addition, the invention also refers to the manufacture of novel compositions with at least one Ginkgoloide and/or acetylcysteine for oral, dietary, oily or local, cosmetic administration. Novel local preparations without ether/volatile oils contain Ginkgoloides with at least one sun screening agent against impairments of pigmentation. The compositions of the invention are used for the manufacture of compounds to protect against alkylacyl-like destabilized cells by preference under the conditions of critical lifestyle.

Abstract: An implant containing a source of oxygen capable of releasing oxygen in the form of molecular oxygen or reactive oxygen species, and a material selected from the group consisting of biodegradable and/or bioactive glass, sol-gel produced silica and mixtures thereof. Also disclosed are uses of the implant and methods of making it.

Abstract: The present application provides dental fillers, and methods of making and using dental fillers that include a treated surface that includes a caseinate. Dental compositions including such dental fillers can be useful for delivering ions to the oral environment. Dental compositions, and methods of using dental compositions that include a caseinate and a hardenable resin or a water-dispersible, polymeric film former are also provided.

Abstract: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

Abstract: The invention relates to compositions for preventing chronic renal failure (CRF) in felines with hyperthyroidism wherein the compositions comprise (1) from about 28 to about 35% protein, the protein comprising at least about 75% vegetable protein, and (2) from about 0.1 to less than about 1 mg/kg iodine and/or from about 0.1 to about 1 mg/kg selenium. The invention also relates to compositions for treating CRF in hyperthyroid felines wherein the compositions comprise (1) from about 28 to about 35% protein, the protein comprising at least about 75% vegetable protein, and (2) from about 0.1 to less than about 0.3 mg/kg iodine and/or from about 0.1 to about 1 mg/kg selenium. The invention further relates to methods for preparing and using such compositions, articles of manufacture comprising such compositions, and means for communicating information about such compositions, methods, and articles of manufacture.

Abstract: The invention disclosed a novel mesoporous silica-based xerogel and its use in hemorrhage control. The mesoporous silica-based xerogel material has tunable mesopores (1-50 nm), high specific surface area (100-1400 m2/g), macroscopical morphology (powder, film, disc, column, etc.) and adjustable compositions (SiO2, CaO and P2O5, etc.) as well as good biodegradation. The mesoporous silica-based xerogels herein effectively promote the blood clotting under various conditions including slow and severe hemorrhage, even at the blood oozing site of bone defect. Meanwhile, the networks of silica-based xerogel with good elastic and mechanic properties, formed by adsorbing a large amount of water, can modulate the cell behavior and tissue growth, and thus promote the wound healing. Additionally, due to the mesoporous structure, the materials have the potential to load drug, thrombin and bioactive factors, which is favorable for the therapeutical efficacy.

Abstract: Compositions and methods that yield chlorine dioxide upon mixing with an aqueous solution.

Abstract: The invention relates to a method for inhibiting the biological acidification of water which is in contact with materials containing sulfur in reduced form or with elemental sulfur, susceptible to oxidation on the part of Thiobacilli, comprising putting said materials in contact with soluble inorganic salts at concentrations ranging from 0.4 normal to saturation.

Abstract: The present invention relates to a method of facilitating the birth process of placental mammals, especially to a method of reducing delays in the birth process and, thereby, complications resulting there from that may negatively affect the health and wellbeing of the mother and increase the incidence of stillbirths and/or neonatal mortality. According to the present invention delays in parturition that result from maternal and/or uterine exhaustion may be prevented or reduced by the administration of an effective amount of one or more psychomotor stimulants to the parturient mammal prior to and/or during parturition. Said psychomotor stimulant is selected from the group comprising xanthines and amphetamines.

Abstract: The present invention relates to compositions and methods for preventing and treating osteochondrosis by administration of supplemental boron containing compounds to animals and humans. The supplemental boron containing compounds are provided in animal feed compositions or as supplements for animal feed. Also provided by this invention are animal feed compositions that are supplemented with boron containing compounds and which have reduced phosphorus content. The invention also provides a method for treating or preventing osteochondrosis in animals or humans by the administration of supplemental boron containing compounds. The invention also provides a method for decreasing the amount of phosphorus excreted by an animal, a method of increasing the efficiency of absorption of phosphorus by an animal, a method of reducing environmental phosphorus pollution by administering supplemental boron to the animal.

Abstract: The present invention relates to compositions including medium chain peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism. The compositions can include advantageously high levels of the medium chain peroxycarboxylic acid, can be readily made, and/or can exhibit reduced odor.

Abstract: A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a “maintenance” phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.

Abstract: The use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood.

Abstract: The present invention utilizes a combination of a porous carrier and an adsorbent such as a molecular sieve to make a more effective hemostatic device to treat wounds in mammalian animals. These hemostatic devices contain additives that do not inhibit hemostasis.

Abstract: A method for the treatment of cancer, particularly a metastatic melanoma or a neoplastic lesion, the method comprising intralesional administration of a hydrophilic vehicle comprising 4,5,6,7-Tetrachloro-2?,4?,5?,7?-tetraiodofluorescein, or a physiologically acceptable salt thereof, at a concentration of about 0.1 w/v % up to about 20 w/v % and an electrolyte comprising at least one cation selected from the group consisting of sodium, potassium, calcium and magnesium and at least one anion selected from the group consisting of chlorine, a phosphate and a nitrate, wherein the electrolyte is at a concentration of between about 0.1 w/v % and about 2 w/v % and the pH of the solution between about 4 to about 10.

Abstract: The subject invention relates to novel compositions containing a diffusion enhancing compound and their use in treating a variety of disorders.

Abstract: The present disclosure relates to a drug and/or food supplement with antiviral effects, in particular for the preventive and/or therapeutic treatment of herpes labialis and/or herpes genitalis, and/or with antibacterial and/or immunomodulating and/or antiphlogistic effects and/or for the preventive and/or therapeutic treatment of affections of the prostate, containing NISYLEN® and/or Cepa and/or Euphrasia and/or Belladonna and/or Mercurius solubilis.

Abstract: A method of providing a rapid, broad spectrum bacterial control, and a rapid persistent antiviral control on a surface, and particularly a mammalian skin surface, is disclosed. In the method, a compound or composition capable of lowering skin pH to less than about 4 is applied to the skin, and preferably is allowed to remain on the skin.

Abstract: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.

Abstract: The invention relates to a preparation having an improved taste, as well as to the use of said preparation for treatment of mineral deficiency. In accordance with the invention, it has been found possible to effectively mask the bad taste of even such notorious minerals as iron. As a result, patient compliance may be increased significantly by prescription of a preparation according to the invention, thereby increasing effective uptake of the deficient mineral.

Abstract: Compositions and formulations are provided comprising a growth factor fraction and at least one glucan. Also provided are methods for making the compositions and formulations. Methods of promoting growth in an animal using the compositions and/or formulations are also provided.

Abstract: The invention relates to a transport system (1) for active substances containing hybrid particles (2) comprising at least one layer of lipid molecules (3) and at least one ligand, the ligand being a peptide (5).

Abstract: antiperspirant compositions comprise an antiperspirant active and a carrier oil in which the carrier oil comprises an aromatic ester oil obeying the general formula: R1—CO2—X—Y—R2 in which R1 and R2 each represent a phenyl group, X represents an alkylene group containing from 2 to 4 carbons including at least one pendant alkyl group and Y represents a bond, or an ether or ester linkage.

Abstract: Combinations of a polyunsaturated fatty acid and diindolylmethane and pharmaceutical composition containing such combinations. Further provided are combinations including a polyunsaturated fatty acid, diindolylmethane, and folic acid. Also provided are combinations including diindolylmethane and folic acid. Also provided is a method for increasing the number of normal cells and decreasing the number of aberrant cells in a subject having the steps of administering to the subject a combination comprising a polyunsaturated fatty acid and diindolylmethane.

Abstract: The invention is a silicon substituted oxyapatite compound (Si—OAp) for use as a synthetic bone biomaterial either used alone or in biomaterial compositions. The silicon substituted oxyapatite compound has the formula Ca5(PO4)3-x(SiO4)xO(1-x)/2, where 0<x<1.0.

Abstract: This invention is directed to compositions for animal consumption (including foods, treats, etc.), particularly compositions that tend to improve kidney function, and particularly compositions that comprise enhanced antioxidants and reduced quantities of protein and/or phosphorus. This invention also is directed generally to methods for using such compositions.

Abstract: The present invention relates to novel urea-formaldehyde polymers coated with an active ingredient, a method of making the same, and their use.

Abstract: This invention relates to quinoline derivatives of formula I wherein R1, R2, R3 are each independently halogen, hydroxy, cyano, amino, nitro, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C4-alkyl, C1-C6-alkoxy, C2-C6-alkenyloxy, C2-C6-alkynyloxy, C1-C4-alkoxy-C1-C4-alkoxy, C3-C7-cycloalkyl-C1-C4-alkoxy, C(OH)(CF3)2, C1-C6-haloalkyl, C1-C6-haloalkoxy, C1-C6-alkylthio, C1-C6-haloalkylthio, C1-C6-alkylsulfinyl, C1-C6-haloalkylsulfinyl, C1-C6-alkylsulfonyl, C1-C6-haloalkylsulfonyl, C(Ra)?O, C(Ra)?NORb, C(?O)ORx, or C(?O)NRxRy; Ra is hydrogen or C1-C4-alkyl; Rb is hydrogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, or C2-C4-haloalkenyl; Rx, Ry are each independently hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-thioalkyl-C1-C4-alkyl, C1-C4-alkyl-S(?O)C1-C4-alkyl, C1-C4-alkyl-S(?O)2C1-C4-alkyl, C3-C6-cyloalkyl, C1-C4-alkyl-C3-C6-cycloalkyl, C3-C6-alkenyl, C3-C6-alkinyl; R4, R5, R6, R7 are each independently hydrogen, halogen, cyano,

Abstract: The present invention provides a method for mineralizing commercially available guided bone regeneration membranes. The method comprises the steps of (a) providing a commercially available guided bone regeneration membrane, (b) applying a mineralizing solution, and (c) microwaving the membrane. The method may further comprise (d) rinsing the membrane in a solution such as distilled water and (e) drying the membrane. The mineralizing solution may be a solution capable of supplying or delivering a mineral such as calcium or zinc. The invention further provides guided bone regeneration membranes made by the methods described. The guided bone regeneration membrane comprises a mineral, such as, for instance calcium or zinc at a weight percent of at least 5%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20% or at least 25% (weight percent) of the membrane. Further, the invention provides methods for enhancing bone regeneration and methods for inhibiting bacterial infection and inflammation.

Abstract: The present invention provides compositions and methods for improving stool quality of a puppy by adjusting the balance of metabolizable cations to metabolizable anions consumed by the puppy.

Abstract: The present invention relates to a composition for organ preservation, comprising an inulin type fructan as an active ingredient. The composition for organ preservation can suppress the hypofunction of an organ and damage to a histological structure and can improve the state of preservation of the organ in the course of organ transplantation and the like.

Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.